Novel Biomarkers Show Promise for Monitoring Anti-TNF Therapy in IBD
While faecal calprotectin, CRP, and drug/antibody levels remain the standard biomarkers for evaluating anti-TNF efficacy in inflammatory bowel disease, emerging candidates including mucosal cytokine transcripts, microRNAs, proteomics profiles, and gut microbiota signatures may offer superior predictive performance. Robust validation studies comparing current and novel biomarkers are urgently needed to advance personalised anti-TNF therapy selection in clinical practice.
The original study
Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers.
- Authors
- Cui G, Fan Q, Li Z, Goll R, Florholmen J
- Journal
- EBioMedicine
- Type
- Journal Article, Review
- PMID
- 33862588
Original abstract
Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal biomarker analysis revealed that faecal calprotectin, C-reactive protein, serum or mucosal concentrations of anti-TNF monoclonal antibodies (mAbs) and antibodies to anti-TNF mAbs are commonly used as current biomarkers in the evaluation of anti-TNF therapeutic efficacy. However, mucosal cytokine transcripts. microRNAs, proteomics and faecal and mucosal gut microbiota profile and mucosal histological features are reported to be novel candidates of biomarkers with high clinical utility in the evaluation of anti-TNF therapeutic efficacy in patients with IBD. Therefore, a robust validation of novel promising biomarkers and comparison studies between current used and novel biomarkers are urgently required to improve their value in the evaluation of therapeutic efficacy and optimization of personalized medicine and identification of IBD candidates for anti-TNF therapy in future clinical practice.